← FDA DRUG APPROVALS

FDA NDA · NDA021735

TERCONAZOLE VAGINAL CREAM 0.8%

terconazole

Sponsor: FOUGERA PHARMS INC

APPLICATION
NDA021735
TYPE
NDA
ORIGINAL APPROVAL
2004-10-01
LATEST ACTION
2025-08-22
ROUTE
VAGINAL
DOSAGE FORM
CREAM
MARKETING STATUS
Prescription

Products

TERCONAZOLE · ReferencePrescription
TERCONAZOLE 0.8% · CREAM · VAGINAL

Approval history

2025-08-22Labeling · Supplement 14 · standardLabelAP
2013-01-16Manufacturing (CMC) · Supplement 5 · standardAP
2010-12-30Labeling · Supplement 4 · unknownLetterAP
2004-10-01Type 5 - New Formulation or New Manufacturer · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →